RADFORD, Va., Sept. 12 /PRNewswire-FirstCall/ -- Presenting today at the
Bear Stearns 18th Annual Healthcare Conference, management for New River
Pharmaceuticals Inc. (Nasdaq: NRPH) provided results from a pharmacokinetic
clinical study on New River's second compound under development, NRP290, a
hydrocodone derivative for the treatment of pain.
RJ Kirk, New River's president and CEO, and Krish Krishnan, CFO and COO,
presented at the conference results of a single dose pharmacokinetic study to
assess oral bioavailability of hydrocodone from NRP290 and acetaminophen
tablets, as compared to hydrocodone bitartrate and acetaminophen tablets in
fasted state in healthy adult volunteers. The results of the study showed
comparable bioavailability and the absence of intact NRP290 conjugates in the
bloodstream.
About New River
New River Pharmaceuticals Inc. is a specialty pharmaceutical company
focused on developing novel pharmaceuticals that are generational improvements
of widely prescribed drugs in large and growing markets.
For further information on New River, please visit the Company's Web site
at http://www.nrpharma.com.
"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT
OF 1995
This press release contains certain forward-looking information that is
intended to be covered by the safe harbor for "forward-looking statements"
provided by the Private Securities Litigation Reform Act of 1995. Forward-
looking statements are statements that are not historical facts. Words such as
"expect(s)," "feel(s)," "believe(s)," "will," "may," "anticipate(s)" and
similar expressions are intended to identify forward-looking statements.
These statements include, but are not limited to, financial projections and
estimates and their underlying assumptions; statements regarding plans,
objectives and expectations with respect to future operations, products and
services; and statements regarding future performance. Such statements are
subject to certain risks and uncertainties, many of which are difficult to
predict and generally beyond the control of New River Pharmaceuticals, that
could cause actual results to differ materially from those expressed in, or
implied or projected by, the forward-looking information and statements.
These risks and uncertainties include: those discussed and identified in the
New River Pharmaceuticals Inc. annual report on Form 10-K, filed with the SEC
on April 1, 2005; the timing, progress and likelihood of success of our
product research and development programs; the timing and status of our
preclinical and clinical development of potential drugs; the likelihood of
success of our drug products in clinical trials and the regulatory approval
process; our drug products' efficacy, abuse and tamper resistance, onset and
duration of drug action, ability to provide protection from overdose, ability
to improve patients' symptoms, incidence of adverse events, ability to reduce
opioid tolerance, ability to reduce therapeutic variability, and ability to
reduce the risks associated with certain therapies; the ability to develop,
manufacture, launch and market our drug products; our projections for future
revenues, profitability and ability to achieve certain sales targets; our
estimates regarding our capital requirements and our needs for additional
financing; the likelihood of obtaining favorable scheduling and labeling of
our drug products; the likelihood of regulatory approval under Section
505(b)(2) under the Federal Food, Drug, and Cosmetic Act; our ability to
develop safer and improved versions of widely-prescribed drugs using our
Carrierwave (TM) technology; and our ability to obtain favorable patent
claims. Readers are cautioned not to place undue reliance on these forward-
looking statements that speak only as of the date hereof. New River
Pharmaceuticals does not undertake any obligation to republish revised
forward-looking statements to reflect events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events. Readers are also
urged to carefully review and consider the various disclosures in New River
Pharmaceuticals' annual report on Form 10-K, filed with the SEC on April 1,
2005, as well as other public filings with the SEC.
Contacts:
The Ruth Group
John Quirk (investors)
646-536-7029
jquirk@theruthgroup.com
Zack Kubow (media)
646-536-7020
zkubow@theruthgroup.com
SOURCE New River Pharmaceuticals Inc.
 back to top
Related links:
http://www.nrpharma.com
CONTACT:
investors - John Quirk, +1-646-536-7029,
jquirk@theruthgroup.com, or media - Zack Kubow, +1-646-536-7020,
zkubow@theruthgroup.com, both of The Ruth Group for New River
Pharmaceuticals Inc.
|
